It is possible that the decreased MFN2 at this early stage of AD contributed to the failure of mitochondrial quality control and contributed to the mitochondrial dysfunction observed at the same age, a hypothesis worthy of testing. This evidence concerns the gene MFN2 and Alzheimer disease.